This Article Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Fisk, B. Articles by Ioannides, C. G. Search for Related Content PubMed PubMed Citation Articles by Fisk, B. Articles by Ioannides, C. G.

Increased Sensitivity of Adriamycin-selected Tumor Lines to CTL-mediated Lysis Results in Enhanced Drug Sensitivity¹

Departments of Gynecologic Oncology [B. F., C. G. I.] and Immunology [C. G. I.], The University of Texas M. D. Anderson Cancer Center, and The University of Texas Medical School-Houston [B.F.], Houston, Texas 77030

The emergence of drug resistance to chemotherapeutic agents is a major cause of treatment failure in cancer therapy. Therefore, much effort has been aimed at circumventing or reversing this undesired effect. Recently, we found that tumor cell lines selected for their multidrug-resistant phenotype can also exhibit increased levels of TAP mRNA and MHC class I proteins. This raised the question of whether drug-resistant tumors are more readily recognized by MHC-restricted CTLs. In this report, we show that five of five MHC class I⁺ tumor cell lines grown in medium containing Adriamycin developed into variants that expressed higher levels of MHC class I than did their corresponding parental cell lines. This was not observed with a MHC class I^- cell line. No similar association was noted for changes in the expression of either HER-2 or intercellular adhesion molecule 1 protein. We also found that MHC class I⁺ drug-selected variants were more readily lysed by MHC-restricted, tumor-associated CTLs than were the drug-sensitive parental cell lines. When the drug-selected variants were cocultured with the same CTLs to eliminate tumor cells expressing higher levels of MHC-I (MHC-^hi), the CTL-resistant tumor cells exhibited a drug sensitivity profile similar to that of the parental cell lines that were not exposed to Adriamycin. These findings suggest that certain chemotherapeutic drugs may increase the immunogenicity of some tumors, and that CTL immunotherapy may help reverse drug resistance.

¹ Supported by a scholarship from the Health Professions Program provided by the United States Department of the Army (to B. F.) and by Grant DAMD 17-94-J-4313 (to C. G. I.).

² To whom requests for reprints should be addressed, at Department of Gynecologic Oncology, The University of Texas M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Box 67, Houston, TX 77030. Phone: (713) 792-2849; Fax: (713) 792-7586.

Received 7/22/98. Accepted 9/18/98.

This article has been cited by other articles:

				C. L. Efferson, N. Tsuda, K. Kawano, E. Nistal-Villan, S. Sellappan, D. Yu, J. L. Murray, A. Garcia-Sastre, and C. G. Ioannides Prostate Tumor Cells Infected with a Recombinant Influenza Virus Expressing a Truncated NS1 Protein Activate Cytolytic CD8+ Cells To Recognize Noninfected Tumor Cells J. Virol., January 1, 2006; 80(1): 383 - 394. [Abstract] [Full Text] [PDF]

				S. Yang and F. G. Haluska Treatment of Melanoma with 5-Fluorouracil or Dacarbazine In Vitro Sensitizes Cells to Antigen-Specific CTL Lysis through Perforin/Granzyme- and Fas-Mediated Pathways J. Immunol., April 1, 2004; 172(7): 4599 - 4608. [Abstract] [Full Text] [PDF]